Physician profile
Jorge Murillo
NPI 1467496398
$53,020.82
in general payments reported to CMS, 2019-2025
29 companies · $3,389 in 2025
The $3,389 reported for 2025 was more than what 89% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $7,163 · 2021: $4,139 · 2022: $2,021 · 2023: $7,404 · 2024: $3,483 · 2025: $3,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,286 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,850 · Consulting Fee: $1,940 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,286.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,850.00 |
| Consulting Fee | $1,940.00 |
| Education | $199.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14,050.61 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Insmed, INC. | $7,648.38 | 2019-2025 | Arikayce, Brinsupri |
| Astellas Pharma US INC | $5,539.48 | 2019-2024 | Cresemba |
| Allergan, INC. | $4,644.76 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $4,549.55 | 2019-2025 | Nuzyra |
| Abbvie INC. | $3,891.70 | 2021-2025 | |
| Gilead Sciences, INC. | $2,458.97 | 2019-2025 | Biktarvy |
| Ferring Pharmaceuticals INC. | $2,241.17 | 2023-2025 | Rebyota |
| Viiv Healthcare Company | $2,001.31 | 2019-2025 | Dovato, Cabenuva |
| La Jolla Pharmaceutical Company | $1,309.11 | 2021-2025 | Xacduro, Xerava, Zevtera |
| Shionogi INC | $1,301.30 | 2022-2025 | Fetroja |
| Melinta Therapeutics, LLC | $1,217.55 | 2019-2025 | Vabomere, Rezzayo, Kimyrsa |
| Aimmune Therapeutics, INC. | $325.61 | 2024-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $310.35 | 2019-2023 | Symtuza |
| Janssen Products, LP | $284.97 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $226.11 | 2019 | |
| Napo Pharmaceuticals INC | $217.21 | 2024 | Mytesi |
| Cumberland Pharmaceuticals, INC. | $185.95 | 2025 | Vibativ |
| Cipla USA INC. | $148.02 | 2021 | |
| Glaxosmithkline, LLC. | $102.06 | 2023 | Arexvy |
| Pfizer INC. | $83.68 | 2025 | |
| Boston Scientific Corporation | $67.66 | 2023-2024 | |
| Sk Life Science, INC. | $56.98 | 2021 | |
| Cormedix INC. | $42.87 | 2025 | Defencath |
| Theratechnologies INC. | $33.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.80 | 2020 | |
| Vyera Pharmaceuticals, LLC | $21.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.29 | 2024 | Flumist Quadrivalent |
| Atricure, INC. | $14.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Murillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.